News

Video

BRIGHTSTAR: Local Consolidative Therapy with Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC

Expert oncologist Yasir Elamin, MD, shares data from the BRIGHTSTAR trial and considers how it may inform real-world use of brigatinib in patient with ALK-rearranged metastatic non–small cell lung cancer.

BRIGHTSTAR: Local Consolidative Therapy with Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC

Background

  • ALK tyrosine kinase inhibitors (TKIs) are now the standard of care for patients with ALK-rearranged metastatic NSCLC with impressive response rates in the first line setting
  • Approximately 95% of patients who have an initial response to ALK-TKIs exhibit an incomplete response resulting in residual disease that may enable the emergence of acquired resistance
  • Minimizing or eliminating residual disease with local consolidation therapy (LCT) may delay the development of resistance and improve clinical outcomes

Study Design

  • Patient population had TKI-naïve ALK+ advanced NSCLC
    • Over 18 years of age
    • Documented ALK rearrangement (tissue or liquid biopsy)
    • TKI naïve or first-line brigatinib within ≤ 8 weeks of enrollment
    • At least one site of residual disease for LCT
    • ECOG PS ≤ 2
  • Patients received brigatinib until disease progression or unacceptable toxicity
  • Non-PD patients received local consolidative therapy, stratified by active sites of disease to LCT to all sites or LCT to sites at physician discretion

Objectives

  • Primary objective was safety and tolerability of brigatinib with LCT
  • Secondary objectives included PFS, OS, and TTP on non-LCT lesions
  • Exploratory Objectives included utility of pretreatment, pre-LCT and post-LCT liquid biopsy assessment as a prognostic and predictive biomarker

Results/Conclusions

  • Brigatinib with LCT is safe in patients with ALK-rearranged advanced NSCLC
  • Brigatinib with LCT yielded promising outcomes when compared to historical outcomes: 3-year PFS rate was 66% in Brightstar compared to 47% in the brigatinib arm of ALTA-1L
  • Complete LCT, baseline ALK plasma negativity, and lower post-induction volume, but not number of metastases at baseline (oligo vs poly) were associated with increased benefit for LCT
  • A randomized trial (BrightStar-2) is planned to compare two intensifications strategies, LCT and chemotherapy, with brigatinib alone as first line therapy for ALK+ NSCLC
Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Ivy Riano, MD, of Dartmouth Geisel School of Medicine
Daniel E. Haggstrom, MD
Daniel E. Haggstrom, MD
Phase 3 MIRASOL Trial: Updated Overall Survival Results of Mirvetuximab Soravtansine (MIRV) Versus Investigator’s Choice (IC) Chemotherapy in Patients (pts) With Platinum-Resistant Ovarian Cancer (PROC) and High Folate Receptor-Alpha (FR⍺) Expression
Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.